LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Inicio・Lista de Acciones・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Cerrado

SectorSanidad

19.97 -0.4

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

19.94

Máximo

20.41

Métricas clave
By Trading Economics
Ingresos	-4.6M 52M
Ventas	5.1M 147M
P/B Media del Sector	12.479 35.733
Margen de beneficios	35.553
Empleados	181
EBITDA	5.9M 79M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+64.34% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-130M 2.5B
Apertura anterior	20.37
Cierre anterior	19.97

Noticias sobre sentimiento de mercado

By Acuity

40%

60%

147 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

N/A / 24.28 Soporte y Resistencia

Catalyst Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

8 sept 2025, 23:59 UTC

Adquisiciones, fusiones, absorciones

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8 sept 2025, 22:02 UTC

Principales Movimientos del Mercado

Microsoft Signs $17.4 Billion AI Deal With Nebius

8 sept 2025, 17:01 UTC

Principales Movimientos del Mercado

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8 sept 2025, 17:01 UTC

Principales Movimientos del Mercado

Tron Shares Rise After New Investment From Bravemorning

8 sept 2025, 16:14 UTC

Principales Movimientos del Mercado

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8 sept 2025, 16:13 UTC

Principales Movimientos del Mercado

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8 sept 2025, 23:12 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 sept 2025, 23:12 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

8 sept 2025, 23:12 UTC

Charlas de Mercado

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8 sept 2025, 22:56 UTC

Charlas de Mercado

Worst May Be Over for New Zealand Retailers -- Market Talk

8 sept 2025, 22:23 UTC

Charlas de Mercado

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8 sept 2025, 21:51 UTC

Charlas de Mercado

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8 sept 2025, 21:47 UTC

Principales Movimientos del Mercado

Microsoft Signs $17.4B AI Deal With Nebius

8 sept 2025, 21:33 UTC

Adquisiciones, fusiones, absorciones

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8 sept 2025, 21:20 UTC

Adquisiciones, fusiones, absorciones

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8 sept 2025, 21:19 UTC

Adquisiciones, fusiones, absorciones

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8 sept 2025, 21:18 UTC

Adquisiciones, fusiones, absorciones

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8 sept 2025, 20:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Tech, Media & Telecom Roundup: Market Talk

8 sept 2025, 19:33 UTC

Charlas de Mercado

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8 sept 2025, 19:22 UTC

Charlas de Mercado

U.S. Natural Gas Futures Settle Higher -- Market Talk

8 sept 2025, 19:02 UTC

Charlas de Mercado

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8 sept 2025, 18:24 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 sept 2025, 18:24 UTC

Charlas de Mercado

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8 sept 2025, 17:29 UTC

Charlas de Mercado

Mexican Inflation Seen Little Changed in August -- Market Talk

8 sept 2025, 16:59 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8 sept 2025, 16:36 UTC

Charlas de Mercado

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8 sept 2025, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

8 sept 2025, 16:16 UTC

Ganancias

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8 sept 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

8 sept 2025, 16:04 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Catalyst Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

64.34% repunte

Estimación a 12 Meses

Media 33 USD 64.34%

Máximo 35 USD

Mínimo 31 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

N/A / 24.28Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentimiento

By Acuity

147 / 371 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.